# US 2023/0065527 A1 · Methods and compositions for targeting pd-l1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065527 A1
- Document ID: US20230065527A1
- Status: Published application
- Kind: A1
- Application number: 17/444,947
- Filed: 2021-08-12
- Published: 2023-03-02
- Earliest claimed: 2020-08-17
- Assignees: Aligos Therapeutics, Inc.
- Applicants: Aligos Therapeutics, Inc.
- Inventors: Tongfei Wu; Pierre Jean-Marie Bernard Raboisson; Francois Gonzalvez; Antitsa Dimitrova Stoycheva; Jerome Deval; Cheng Liu; Qingling Zhang
- Web page: https://patentgrep.com/patent/US20230065527A1

## CPC

- A61P 31/20: for DNA viruses
- C07D 487/10: Spiro-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 471/08: Bridged systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

## Claims

### Claim 1

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:
wherein:
X1 is N or CH;
Ring A is selected from the group consisting of:
a monocyclic C5-7 cycloalkyl substituted with R2a1;
a bicyclic C6-12 cycloalkyl substituted with R2a2;
a 5-7 membered nitrogen-containing monocyclic heterocyclyl, wherein a nitrogen of the 5-7 membered nitrogen-containing monocyclic heterocyclyl is optionally substituted with R2a3, wherein a carbon of the 5-7 membered nitrogen-containing monocyclic heterocyclyl is optionally substituted with R2a4 or R2a5, and wherein when R2a5 is present, R2a5 is attached at a carbon atom adjacent to a nitrogen of the 5-7 membered nitrogen-containing monocyclic heterocyclyl;
a 6-12 membered nitrogen-containing bicyclic heterocyclyl, wherein a nitrogen of the 6-12 membered nitrogen-containing bicyclic heterocyclyl is optionally substituted with R2a6;
a 5-7 membered oxygen-containing monocyclic heterocyclyl substituted with R2a7 or R2a8, wherein when R2a8 is present, R2a8 is attached at a carbon atom adjacent to an oxygen of the 5-7 membered oxygen-containing monocyclic heterocyclyl, and the 5-7 membered oxygen-containing monocyclic heterocyclyl does not include any ring nitrogens; and
wherein Ring A is optionally further substituted;
B1 is selected from the group consisting of:
Y1 and Y2 are independently N or —CR8, wherein R8 is selected from the group consisting of hydrogen, —C1-4 alkyl, and —C1-4 haloalkyl;
Y3 are independently N or CH;
Z2 is O or NH;
R1, R6a1 and R6a2 are independently selected from the group consisting of —C1-4 alkyl, —C1-4 haloalkyl, -monocyclic C3-6cycloalkyl, —(C1-4alkyl)monocyclic C3-6cycloalkyl, 4-6 membered monocyclic heterocyclic ring, aryl(C1-4alkyl) and —(C1-4 alkyl)5- or 6-membered monocyclic heteroaryl; wherein the —C3-6cycloalkyl, the 4-6 membered monocyclic heterocyclyl, the aryl(C1-4alkyl) and the -5- or 6-membered monocyclic heteroaryl(C1-4alkyl) is optionally substituted with one or two or three substituents independently selected from the group consisting of halogen, CN, C1-4 alkyl, C3-6 monocyclic cycloalkyl and C1-4 alkoxy;
R2a1, R2a2 and R2a7 are independently selected from the group consisting of amino, —N(Rm1)Rn1, —(C3-6 monocyclic cycloalkyl)N(Rm2)Rn2, —Rx1 and —(C1-4 alkyl)Rx1,
Rm1 and Rm2 are independently selected from the group consisting of hydrogen, —C1-4 alkyl, C3-6 monocyclic cycloalkyl, C5-12 bicyclic cycloalkyl, 5- or 6-membered monocyclic heteroaryl, 4-7 membered monocyclic heterocyclyl, 8-11 membered fused-heteroaryl, 8-11 membered fused-heterocyclyl and —Rx2; wherein the monocyclic heteroaryl, the bicyclic heteroaryl the monocyclic heterocyclyl and the bicyclic heterocyclyl contain at least one heteroatom independently selected from the group consisting of O, S, C(═O), S(═O), S(═O)2 and N; wherein the —C1-4 alkyl is optionally substituted with one or two or three substituents independently selected from the group consisting of halogen, cyano, hydroxy, —C1-4 alkoxy, —C1-4 haloalkyl, —C1-4 haloalkoxy, —C(═O)ORZ1, —C(═O)NHS(═O)2RZ3, —C(═O)N(RZ1)RZ2, —S(═O)2RZ3, —S(═O)2N(RZ1)RZ2, —N(RZ1)C(═O)RZ3, —N(RZ1)S(═O)RZ3, N(RZ1)C(═O)N(RZ2)RZ3 and —N(RZ1)S(═O)N(RZ2)RZ3; wherein the C3-6 monocyclic cycloalkyl, the C3-6 monocyclic cycloalkyl(C1-4 alkyl), the 5- or 6-membered monocyclic heteroaryl, the 4-7 membered monocyclic heterocyclyl, the 8-11 membered fused-heteroaryl, the 8-11 membered fused-heterocyclyl and the 4-7 membered monocyclic heterocyclyl(CH2) are optionally substituted with one or two or three substituents independently selected from the group consisting of halogen, cyano, —C1-4 alkyl, hydroxy, —C1-4 alkoxy, —C1-4 haloalkyl, —C1-4 haloalkoxy, —C(═O)ORZ1, —C(═O)NHS(═O)2RZ3, —C(═O)N(RZ1)RZ2, —S(═O)2RZ3, —S(—0)2N(RZ1)RZ2, —N(RZ1)C(═O)RZ3, —N(RZ1)S(═O)RZ3, —N(RZ1)C(═O)N(RZ2)RZ3 and —N(RZ1)S(═O)N(RZ2)RZ3; and Rn1 and Rn2 is hydrogen, —C1-4 alkyl, —C1-4 halolkyl or C3-6 monocyclic cycloalkyl(CH2);
R2a3 and R2a6 are independently selected from the group consisting of hydrogen, —C1-4 alkyl, C3-6 monocyclic cycloalkyl, C5-12 bicyclic cycloalkyl, 5- or 6-membered monocyclic heteroaryl, 4-7 membered monocyclic heterocyclyl, 8-11 membered fused-heteroaryl, 8-11 membered fused-heterocyclyl and —Rx2; wherein the monocyclic heteroaryl and the monocyclic heterocyclyl contain at least one heteroatom independently selected from the group consisting of O, S, C(═O), S(═O), S(═O)2 and N; wherein the —C1-4 alkyl, the —C3-6 monocyclic cycloalkyl, the —C3-6 monocyclic cycloalkyl(C1-4 alkyl), the 5- or 6-membered monocyclic heteroaryl, the 4-7 membered monocyclic heterocyclyl and the 4-7 membered monocyclic heterocyclyl(CH2) are optionally substituted with one or two or three substituents independently selected from the group consisting of halogen, cyano, hydroxy, —C1-4 alkoxy, —C1-4 haloalkoxy, —C(═O)ORZ1, —C(═O)NHS(═O)2RZ3, —C(═O)N(RZ1)RZ2, —S(═O)2RZ3, —S(═O)2N(RZ1)RZ2, —NHC(═O)RZ3, —NHC(═O)N(RZ1)RZ3 and —N(RZ1)S(═O)2N(RZ2)RZ3;
R2a4 is selected from the group consisting of halogen, —C1-4 alkyl, —C(═O)ORZ4, —ORZ4, —N(Rm3)Rn3 and —C3-7 cycloalkyl; wherein the —C1-4 alkyl and the —C3-7 cycloalkyl are optionally substituted with one or two or three substituents independently selected from the group consisting of halogen, cyano, hydroxy, —C1-4 alkoxy, —C1-4 haloalkoxy, —C(═O)ORZ1, —C(═O)NHS(═O)2RZ3, —C(═O)N(RZ1)RZ2, —S(═O)2RZ3, —S(═O)2N(RZ1)RZ2, —NHC(═O)RZ3, —NHC(═O)N(RZ1)RZ3 and —N(RZ1)S(═O)2N(RZ2)RZ3; wherein Rm3 and Rn3 are independently selected from the group consisting of hydrogen, —C1-4 alkyl and —C3-6 monocyclic cycloalkyl; and RZ4 is selected from the group consisting of hydrogen, —C1-4 alkyl, —C1-4 haloalkyl and —C3-6 cycloalkyl;
R2a5 and R2a8 are independently selected from the group consisting of —C1-4 alkyl, —C(═O)ORZ5, —C3-6 monocyclic cycloalkyl and —(C1-4 alkyl)Rx1; wherein the —C1-4 alkyl and the —C3-6 monocyclic cycloalkyl are optionally substituted with one or two or three substituents independently selected from the group consisting of halogen, cyano, hydroxy, —C1-4 alkoxy, —C1-4 haloalkoxy, —C(═O)ORZ1, —C(═O)NHS(═O)2RZ3, —C(═O)N(RZ1)RZ2, —S(═P)2RZ3, —S(═O)2N(RZ1)RZ2, —NHC(═O)RZ3, —NHC(═O)N(RZ1)RZ3 and —N(RZ1)S(═O)2N(RZ2)RZ3; and wherein RZ5 is hydrogen, —C1-4 alkyl, —C1-4 haloalkyl and —C3-6 cycloalkyl;
R3a, R3b, R3c, R3e, R3f and R3g are independently selected from the group consisting of hydrogen and halogen;
R3d and R3h are independently selected from the group consisting of hydrogen, halogen, cyano, —CH3, —CH2CH3, —CH2OH, —OCH3 and —SCH3;
R4a1, R4a2 and R4a3 are independently selected from the group consisting of amino, —NRp1Rq1, —(C3-6 monocyclic cycloalkyl)N(Rp2)Rq2, —Ry1 and —(C1-4 alkyl)Ry1;
Rp1 and Rp2 are independently selected from the group consisting of hydrogen, —C1-4 alkyl, C3-6 monocyclic cycloalkyl, C5-12 bicyclic cycloalkyl, 5- or 6-membered monocyclic heteroaryl, 4-7 membered monocyclic heterocyclyl, 8-11 membered fused-heteroaryl, 8-11 membered fused-heterocyclyl and —Ry2; wherein the monocyclic heteroaryl, the bicyclic heteroaryl the monocyclic heterocyclyl and the bicyclic heterocyclyl contain at least one heteroatom independently selected from the group consisting of O, S, C(═O), S(═O), S(═O)2 and N; wherein the —C1-4 alkyl is optionally substituted with one or two or three substituents independently selected from the group consisting of halogen, cyano, -hydroxy, —C1-4 alkoxy, —C1-4 haloalkyl, —C1-4 haloalkoxy, —C(═O)ORW1, —C(═O)NHS(═O)2RW3, —C(═O)N(RW1)RW2, —S(═O)2RW3, —S(═O)N(RW1)RW2, —N(RW1)C(═O)RW3, —N(RW1)S(═O)RW3, —N(RW1)C(═O)N(RW2)RW3 and —N(RW1)S(═O)N(RW2)RW3; wherein the C3-6 monocyclic cycloalkyl, the C3-6 monocyclic cycloalkyl(C1-4 alkyl), the 5- or 6-membered monocyclic heteroaryl, the 4-7 membered monocyclic heterocyclyl, the 8-11 membered fused-heteroaryl, the 8-11 membered fused-heterocyclyl and the 4-7 membered monocyclic heterocyclyl(CH2) are optionally substituted with one or two or three substituents independently selected from the group consisting of halogen, cyano, —C1-4 alkyl, hydroxy, —C1-4 alkoxy, —C1-4 haloalkyl, —C1-4 haloalkoxy, —C(═O)ORW1, —C(═O)NHS(═O)2RW3, —C(═O)N(RW1)RW2, —S(═O)2RW3, —S(═O)N(RW1)RW2, —N(RW1)C(═O)RW3, —N(RW1)S(═O)RW3, —N(RW1)C(═O)N(RW2)RW3 and —N(RW1)S(═O)N(RW2)RW3; and Rp1 and Rq2 are independently hydrogen, —C1-4 alkyl, —C1-4 halolkyl or C3-6 monocyclic cycloalkyl(CH2);
Rx1 is selected from the group consisting of:
wherein Rx1 is optionally substituted with one or two substituents independently selected from the group consisting of halogen, cyano, —C1-4 alkyl, hydroxy, —C1-4 alkoxy, —C1-4 haloalkyl, —C1-4 haloalkoxy, —C(═O)ORZ1, —C(═O)NHS(═O)2RZ3, —C(═O)N(RZ1)RZ2, —S(═O)2RZ3, —S(═O)2N(RZ1)RZ2, —N(RZ1)C(═O)RZ3, —N(RZ1)S(═O)RZ3, —N(RZ1)C(═O)N(RZ1)RZ3 and —N(RZ1)S(═O)2N(RZ2)RZ3;
Rx2 is selected from the group consisting of:
Ry1 is selected from the group consisting of:
wherein Ry1 is optionally substituted with one or two substituents independently selected from the group consisting of halogen, cyano, —C1-4 alkyl, hydroxy, —C1-4 alkoxy, —C1-4 haloalkyl, —C1-4 haloalkoxy, —C(═O)ORW1, —C(═O)NHS(═O)2RW3, —C(═O)N(RW1)RW2, —S(═O)2RW3, —S(═O)N(RW1)12W2, —N(RW1)C(═O)RW3, —N(RW1)S(═O)RW3, —N(RW1)C(═O)N(RW2)RW3 and —N(RW1)S(═O)N(RW2)RW3;
Ry2 is selected from the group consisting of:
R5a1 and R5b1 are independently selected from the group consisting of hydrogen, —C1-4 alkyl, —C1-4 haloalkyl, —C1-4 alkoxy and —C1-4 haloalkoxy; or
R5a1 and R5b1 are taken together along with the atom to which R5a1 and R5b1 are attached to form monocyclic —C3-6 cycloalkyl or 4-6 monocyclic heterocyclyl, wherein the —C3-6 cycloalkyl or the 4-6 monocyclic heterocyclyl can be optionally further substituted;
R5a2 and R5b2 are independently selected from the group consisting of hydrogen, —C1-4 alkyl, —C1-4 haloalkyl, —C1-4 alkoxy and —C1-4 haloalkoxy; or
R5a2 and R5b2 are taken together along with the atom to which R5a2 and R5b2 are attached to form monocyclic —C3-6 cycloalkyl or 4-6 monocyclic heterocyclyl, wherein the —C3-6 cycloalkyl or the 4-6 monocyclic heterocyclyl can be optionally further substituted;
R5a3 and R5b3 are independently selected from the group consisting of hydrogen, —C1-4 alkyl, —C1-4 haloalkyl, —C1-4 alkoxy and —C1-4 haloalkoxy; or
R5a3 and R5b3 are taken together along with the atom to which R5a3 and R5b3 are attached to form monocyclic —C3-6 cycloalkyl or 4-6 monocyclic heterocyclyl, wherein the —C3-6 cycloalkyl or the 4-6 monocyclic heterocyclyl can be optionally further substituted;
R7a2 and R7a3 are independently selected from the group consisting of hydrogen, halogen, cyano, —C1-4 alkyl, —C1-4 haloalkyl, —C1-4 alkoxy and —C1-4 haloalkoxy;
m1, m2, m3, n1, n2 and n3 are independently 1 or 2;
m4 and n4 are independently 0, 1 or 2;
RX3 is selected from the group consisting of hydrogen, halogen, —C1-4 alkyl, —C1-4 haloalkyl, —C(═O)RZ3, —C(═O)ORZ1, —S(═O)2RZ1, —C(═O)N(RZ1)RZ2 and —S(═O)N(RZ1)RZ2;
RY3 is selected from the group consisting of hydrogen, halogen, —C1-4 alkyl, —C1-4 haloalkyl, —C(═O)RZ3, —C(═O)ORZ3, —S(═O)2RW3, —C(═O)N(RW1)RW2 and —S(═O)N(RW1)RW2;
RZ1, RZ2, RW1 and RW2 are independently selected from the group consisting of hydrogen, —C1-4 alkyl, and —C1-4 haloalkyl; and
RZ3 and RW3 are independently selected from the group consisting of hydrogen, —C1-4 alkyl and —C1-4 haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein a compound of Formula (II), or a pharmaceutically acceptable salt thereof, having the structure:

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The compound of claim 2; wherein R4a1 is —Ry1; and R5a1 and R5b1 are each hydrogen.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, wherein a compound of Formula (III), or a pharmaceutically acceptable salt thereof, having the structure:

### Claim 8

(canceled)

### Claim 9 (depends on 7)

The compound of claim 7, wherein R4a2 is —Ry1; and R5a2 and R5b2 are each hydrogen.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound of claim 1, wherein a compound of Formula (IV), or a pharmaceutically acceptable salt thereof, having the structure:

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The compound of claim 13, wherein R4a3 is —Ry1; and R5a3 and R5b3 are each hydrogen.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 4)

The compound of claim 4, wherein —Ry1 is selected from the group consisting of:

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The compound of claim 1, wherein Ring A is a monocyclic C5-7 cycloalkyl substituted with R2a1.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 25)

The compound of claim 25, wherein R2a1 is —Rx1, wherein —Rx1 is selected from the group consisting of:
or wherein R2a1 is selected from the group consisting of:

### Claim at position 33

-49. (canceled)

### Claim 50 (depends on 1)

The compound of claim 1, wherein Ring A is a 5-7 membered nitrogen-containing monocyclic heterocyclyl, wherein a nitrogen of the 5-7 membered nitrogen-containing monocyclic heterocyclyl is optionally substituted with R2a3, wherein a carbon of the 5-7 membered nitrogen-containing monocyclic heterocyclyl is optionally substituted with R2a4 or R2a5, and wherein when R2a5 is present, R2a5 is attached at a carbon atom adjacent to a nitrogen of the 5-7 membered nitrogen-containing monocyclic heterocyclyl is selected from the group consisting of:
wherein asterisks indicate the position of the fused bond, and R2a4 and R2a5 are each optionally present; or wherein Ring A is a 5-7 membered oxygen-containing monocyclic heterocyclyl substituted with R2a7 or R2a8; wherein R2a8 is attached at a carbon atom adjacent to an oxygen of the 5-7 membered oxygen-containing monocyclic heterocyclyl, and the 5-7 membered oxygen-containing monocyclic heterocyclyl does not include any ring nitrogens is selected from the group consisting of:
wherein asterisks indicate the position of the fused bond, and R3a7 or R3a8 is present.

### Claim at position 35

-72. (canceled)

### Claim 73 (depends on 50)

The compound of claim 50, wherein R2a7 is —Rx1, wherein —Rx1 is selected from the group consisting of:
or R2a7 is selected from the group consisting of:

### Claim at position 37

-84. (canceled)

### Claim 85 (depends on 1)

The compound of claim 1, wherein
R1 is —C1-4 alkyl.

### Claim at position 39

-91. (canceled)

### Claim 92 (depends on 1)

The compound of claim 1, wherein R3a, R3b, R3c, R3e, R3f and R3g are each hydrogen; and R3d and R3h are each halogen; or wherein R3a, R3b, R3c, R3e, R3f and R3g are each hydrogen; and R3d is halogen; and R3h is —CH3.

### Claim at position 41

-95. (canceled)

### Claim 96 (depends on 1)

The compound of claim 1 selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 97 (depends on 1)

The compound of claim 1 selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 98 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and excipient.

### Claim 99 (depends on 1)

A method for treating hepatitis B in a subject comprising administering to the subject in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 100 (depends on 1)

A method for treating hepatocellular carcinoma (HCC) in a subject comprising administering to the subject in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 47

-107. (canceled)

### Claim 108 (depends on 9)

The compound of claim 9, wherein —Ry1 is selected from the group consisting of:

### Claim 109 (depends on 15)

The compound of claim 15, wherein —Ry1 is selected from the group consisting of:
